HomeCompareTCTZF vs ABBV

TCTZF vs ABBV: Dividend Comparison 2026

TCTZF yields 1.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCTZF wins by $5.77M in total portfolio value· pulled ahead in Year 6
10 years
TCTZF
TCTZF
● Live price
1.08%
Share price
$63.10
Annual div
$0.68
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.88M
Annual income
$4,986,415.06
Full TCTZF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TCTZF vs ABBV

📍 TCTZF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCTZFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCTZF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCTZF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCTZF
Annual income on $10K today (after 15% tax)
$91.60/yr
After 10yr DRIP, annual income (after tax)
$4,238,452.80/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TCTZF beats the other by $4,217,396.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCTZF + ABBV for your $10,000?

TCTZF: 50%ABBV: 50%
100% ABBV50/50100% TCTZF
Portfolio after 10yr
$2.99M
Annual income
$2,505,593.41/yr
Blended yield
83.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TCTZF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
4.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCTZF buys
0
ABBV buys
0
No recent congressional trades found for TCTZF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCTZFABBV
Forward yield1.08%3.06%
Annual dividend / share$0.68$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$5.88M$102.3K
Annual income after 10y$4,986,415.06$24,771.77
Total dividends collected$5.78M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: TCTZF vs ABBV ($10,000, DRIP)

YearTCTZF PortfolioTCTZF Income/yrABBV PortfolioABBV Income/yrGap
1$10,916$215.53$11,550$430.00$634.00ABBV
2$12,119$439.74$13,472$627.96$1.4KABBV
3$13,880$912.60$15,906$926.08$2.0KABBV
4$16,806$1,953.65$19,071$1,382.55$2.3KABBV
5$22,403$4,421.28$23,302$2,095.81$899.00ABBV
6← crossover$34,988$11,016.71$29,150$3,237.93+$5.8KTCTZF
7$69,597$32,159.45$37,536$5,121.41+$32.1KTCTZF
8$194,039$119,570.11$50,079$8,338.38+$144.0KTCTZF
9$830,736$623,114.33$69,753$14,065.80+$761.0KTCTZF
10$5,875,302$4,986,415.06$102,337$24,771.77+$5.77MTCTZF

TCTZF vs ABBV: Complete Analysis 2026

TCTZFStock

Tencent Holdings Limited, an investment holding company, provides value-added services (VAS) and Online advertising services in Mainland China and internationally. The company operates through VAS, Online Advertising, FinTech and Business Services, and Others segments. It offers online games and social network services; FinTech and cloud services, and online advertising services. The company is also involved in the production, investment, and distribution of films and television programs for third parties, as well as copyrights licensing, merchandise sales, and other activities. n addition, it develops software; develops and operates online games; and provides information technology, information system integration, asset management, online literature, and online music entertainment services. Tencent Holdings Limited company was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.

Full TCTZF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TCTZF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCTZF vs SCHDTCTZF vs JEPITCTZF vs OTCTZF vs KOTCTZF vs MAINTCTZF vs JNJTCTZF vs MRKTCTZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.